CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02297139
NCT02297139Phase 2Completed
CompareCT.gov

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Bristol-Myers Squibb·interventional·Posted Nov 21, 2014·Updated May 6, 2023

In Brief

A Phase 2 clinical trial evaluating Dasatinib for Multiple Indications Cancer. Completed, enrolled 17 participants across 6 sites in 2 countries.

Detailed Summary

The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Indications Cancer
CountriesFrance, Poland
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 21, 2014
Enrollment StartJul 31, 2015
Primary CompletionMay 15, 2022
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 11.6 years ago

Interventions

Dasatinibdrug